ARAY

Accuray Incorporated

$3.19

-16.49%
SectorHealthcareIndustryMedical DevicesCountryUnited States

Accuray Incorporated engages in the design, development, and sale of radiosurgery and radiation therapy systems for the treatment of tumors throughout the body in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. It also provides the TomoTherapy platform, including the Radixact System, a tailored helical solution, which integrates radiation treatment planning, delivery, imaging, and data management; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems.

Source: Yahoo Finance
AI summary

Price & performance

1M-65.3%
3M-72.5%
YTD-90.6%
1Y-93.2%
52-week range—
Beta1.97
Full chart and returns against a benchmark

Q-Score

33/ 100

Quality against peers; 50 is the peer median.

Growth28
Risk41
Performance23
Valuation57
Profitability43
Leverage33
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2026

Revenue$401.9M-12.3%
Net income-$49.2M
Net margin-12.2%-11.9 pts
Historical fundamentals

Red flags in filings

4active red flags
Material weakness in controlsAug 27, 2026
Restated financialsFeb 9, 2026
Late filing noticeFeb 9, 2026
Filings, findings and the timeline

Revenue exposure

Eimea38%
Americas22%
China17%
Largest customer16%
Regions, segments, customers and suppliers

Valuation

ARAYIndustryP/E—29.61P/S0.023.49EV/EBITDA—18.38P/B0.183.39PEG——
Dividend yield0.00%
Every valuation metric

Earnings

Feb 3next report
EPS estimate—
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate